The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: A meta-analysis of published literatures

Breast Cancer Research and Treatment

Volumn 129, Issue 3, 2011, Pages 839-848

  Du, Yueyao ^a,b   Zhou, Qiong ^a,b   Yin, Wenjin ^a,b   Zhou, Liheng ^a,b   Di, Genhong ^a,b   Shen, Zhenzhou ^a,b   Shao, Zhimin ^a,b   Lu, Jinsong ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Anthracyclines; Breast cancer; Meta analysis; Sensitivity; Topoisomerase II

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN C; TAXANE DERIVATIVE; THIOTEPA; TOPOISOMERASE 2ALPHA; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE; VINDESINE;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SENSITIVITY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; META ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052582851     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-011-1694-9     Document Type: Article

References (19)

1. JM Berger SJ Gamblin SC Harrison JC Wang 1996 Structure and mechanism of DNA topoisomerase II Nature 379 225 232 8538787 10.1038/379225a0 1:CAS:528:DyaK28Xmtl2gsg%3D%3D (Pubitemid 26025206)
2. U Kellner M Sehested PB Jensen F Gieseler P Rudolph 2002 Culprit and victim-DNA topoisomerase II Lancet Oncol 3 235 243 12067686 10.1016/S1470- 2045(02)00715-5 1:CAS:528:DC%2BD38XjsFWjs7Y%3D (Pubitemid 34436660)
3. C Oakman E Moretti F Galardi L Santarpia A Di Leo 2009 The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients Cancer Treat Rev 35 662 667 19758759 10.1016/j.ctrv.2009. 08.006 1:CAS:528:DC%2BD1MXhsVGlsb3J
4. V Durbecq M Paesmans F Cardoso, et al. 2004 Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Mol Cancer Ther 3 1207 1214 15486187 1:CAS:528:DC%2BD2cXosVSrs74%3D (Pubitemid 39440165)
5. A Di Leo D Gancberg D Larsimont, et al. 2002 HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 8 1107 1116 12006526 1:CAS:528:DC%2BD38XksVSqu7s%3D (Pubitemid 34517647)
6. M Martin-Richard M Munoz J Albanell, et al. 2004 Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy Oncology 66 388 394 15331926 10.1159/000079487 1:CAS:528:DC%2BD2cXntFSgt74%3D (Pubitemid 39194361)
7. G MacGrogan P Rudolph I Mascarel Id, et al. 2003 DNA topoisomerase IIalpha expression and the response to primary chemotherapy in breast cancer Br J Cancer 89 666 671 12915875 10.1038/sj.bjc.6601185 1:CAS:528: DC%2BD3sXmtFKqtrg%3D (Pubitemid 37076170)
8. JS Coon E Marcus S Gupta-Burt S Seelig K Jacobson S Chen V Renta G Fronda HD Preisler 2002 Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer Clin Cancer Res 8 1061 1067 11948114 1:CAS:528:DC%2BD38XjsF2ltr8%3D (Pubitemid 35177356)
9. K Park J Kim S Lim S Han 2003 Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy Eur J Cancer 39 631 634 12628842 10.1016/S0959-8049(02)00745-1 1:CAS:528:DC%2BD3sXhvFGkurk%3D (Pubitemid 36287375)
10. C Desmedt E Azambuja D Larsimont, et al. 2009 Predicting the efficacy of anthracyclines in breast cancer (BC) patients: results of the neoadjuvant TOP trial J Clin Oncol 27 523
11. F Cardoso V Durbecq D Larsimont, et al. 2004 Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer Int J Oncol 24 201 209 14654958 1:CAS:528:DC%2BD2cXktlWhtw%3D%3D
12. TA Jarvinen K Holli T Kuukasjarvi JJ Isola 1998 Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer Br J Cancer 77 2267 2273 9649144 10.1038/bjc.1998.377 1:CAS:528:DyaK1cXktlCmtbo%3D (Pubitemid 28263952)
13. AS Knoop H Knudsen E Balslev, et al. 2005 Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group J Clin Oncol 23 7483 7490 16234514 10.1200/JCO.2005.11. 007 1:CAS:528:DC%2BD2MXht1WrsrzK (Pubitemid 46291811)
14. JM Bartlett A Munro DA Cameron J Thomas R Prescott CJ Twelves 2008 Type 1 receptor tyrosine kinase profiles identify patients with enhanced benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial J Clin Oncol 26 5027 5035 18768436 10.1200/JCO.2007.14.6597 1:CAS:528: DC%2BD1cXhsVGhsrrE
15. FP O'Malley S Chia D Tu LE Shepherd MN Levine VH Bramwell IL Andrulis KI Pritchard 2009 Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy J Natl Cancer Inst 101 644 650 19401546 10.1093/jnci/djp067
16. D Slamon W Eiermann N Robert, et al. 2009 Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC → T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC → TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study Cancer Res 69 500S
17. A Di Leo J Isola F Piette, et al. 2009 A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy Cancer Res 69 99S
18. JL Hayward PP Carbone JC Heuson S Kumaoka A Segaloff RD Rubens 1977 Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland Cancer 39 1289 1294 912660 10.1002/1097-0142(197703)39: 3<1289::AID-CNCR2820390340>3.0.CO;2-F 1:STN:280:DyaE1c%2Fit1eksg%3D%3D (Pubitemid 8081207)
19. AU Buzdar 2006 Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer J Clin Oncol 24 2409 2411 16682721 10.1200/JCO.2006.05.9113 (Pubitemid 46630613)